🔍 Definition
Systemic hypertension (HTN) is a chronic medical condition defined as persistently elevated arterial blood pressure — classically ≥130/80 mmHg per the 2017 ACC/AHA Hypertension Guideline, and ≥140/90 mmHg per older JNC 7 criteria. In ICD-10-CM, there are no BP thresholds or severity descriptors (mild/moderate/severe) embedded in the code structure — the classification hinges on documented hypertension type, presumed or documented causality, organ involvement, and complications. The FY 2027 ICD-10-CM Official Guidelines section I.C.9 governs hypertension coding and its presumed causal relationships.
Pulmonary hypertension (PH) is a hemodynamic and pathophysiological state defined as mean pulmonary arterial pressure (mPAP) >20 mmHg at rest by right heart catheterization, with pulmonary arterial wedge pressure (PAWP) and pulmonary vascular resistance (PVR) used to distinguish pre-capillary, post-capillary, and combined forms. Current ESC/ERS guidance defines pre-capillary PH/PAH physiology as mPAP >20 mmHg, PAWP ≤15 mmHg, and PVR >2 Wood units; the older threshold was mPAP ≥25 mmHg. PH encompasses five WHO diagnostic groups with distinct etiologies, treatments, and ICD-10-CM codes. It is distinct from systemic hypertension and is coded in the I27.x category.
Clinical significance for coders and CDI specialists: Hypertension is the most common chronic condition documented in inpatient and outpatient records. Accurate coding — especially capturing hypertensive heart disease (I11.x), hypertensive CKD (I12.x), and the combination (I13.x) — is essential for proper DRG assignment, risk adjustment, quality measures, and HCC capture under CMS HCC Model v28.
Under CMS HCC Model v28 (effective 2024, fully phased in 2026), I10 Essential (primary) hypertension alone does not map to any V28 payment HCC. I10 did not map to a payment HCC in V24 either (V24 HCC 85 was heart failure). Risk is captured only when complications — hypertensive heart disease (I11.x), hypertensive CKD (I12.x), heart failure (I50.x), CKD stage (N18.x) — are documented and coded. Ensure all hypertensive complications are captured with specificity.
🗂️ Alternative Terminology
| Formal / ICD-10-CM Term | Colloquial / Lay / Clinical Synonyms |
|---|---|
| Essential (primary) hypertension (I10) | High blood pressure, HTN, HBP, idiopathic hypertension, benign hypertension (outdated), primary HTN |
| Hypertensive heart disease (I11.x) | Hypertensive cardiomyopathy, HTN heart disease, cardiac hypertension, hypertensive LVH with HF |
| Hypertensive chronic kidney disease (I12.x) | Hypertensive nephropathy, HTN-CKD, hypertensive renal disease, hypertension-related CKD |
| Hypertensive heart and CKD (I13.x) | Cardiorenal hypertension, combined hypertensive HF and renal disease, HTN triad |
| Secondary hypertension (I15.x) | Renovascular HTN, endocrine HTN, secondary HBP, hypertension due to renal artery stenosis |
| Hypertensive urgency (I16.0) | Severe asymptomatic hypertension, BP crisis without end-organ damage, stage 3 HTN (informal) |
| Hypertensive emergency (I16.1) | Malignant hypertension (mostly historical), hypertensive crisis with end-organ damage, accelerated HTN |
| Primary pulmonary arterial hypertension (I27.0) | Idiopathic PAH, primary PH, IPAH, sporadic PAH, Group 1 PAH |
| Secondary pulmonary arterial hypertension (I27.21) | Heritable PAH, drug-induced PAH, CTD-associated PAH, Group 1′ PAH |
| PH due to left heart disease (I27.22) | Passive pulmonary hypertension, Group 2 PH, post-capillary PH, pulmonary venous hypertension |
| PH due to lung diseases/hypoxia (I27.23) | Group 3 PH, hypoxic PH, COPD-related PH, ILD-related PH |
| Chronic thromboembolic PH (I27.24) | CTEPH, Group 4 PH, chronic PE with PH, thromboembolic PH |
| Cor pulmonale, chronic (I27.81) | Pulmonary heart disease, right-sided heart failure from lung disease, chronic RV failure |
| Persistent pulmonary hypertension of newborn (P29.3) | PPHN, persistent fetal circulation, neonatal PH |
| Gestational hypertension (O13.x) | Pregnancy-induced HTN, PIH, transient HTN of pregnancy |
| Preeclampsia (O14.x) | Gestational HTN with proteinuria, toxemia (outdated), pre-eclampsia |
| Eclampsia (O15.x) | Toxemia with seizures (outdated), eclamptic convulsions |
🩺 Signs & Symptoms
Systemic Hypertension
Systemic hypertension is frequently asymptomatic and discovered incidentally. When symptomatic, common manifestations include:
- Headache — classically occipital, worse in the morning; may signal hypertensive urgency/emergency
- Epistaxis — nose bleeds associated with elevated BP
- Visual changes — blurred vision, scotoma in hypertensive retinopathy (H35.0 with the applicable hypertension code from I10–I15; sequence based on reason for encounter)
- Dizziness / lightheadedness
- Palpitations / chest pain — especially with hypertensive heart disease
- Dyspnea — when hypertensive heart failure (I11.0) has developed
- Edema — peripheral or pulmonary when concurrent heart failure or CKD is present
- Hematuria, proteinuria — signs of hypertensive nephropathy (I12.x)
- End-organ damage signs in HTN emergency (I16.1): papilledema, focal neurological deficits, AKI (elevated creatinine), chest pain (AMI/aortic dissection), pulmonary edema
Pulmonary Hypertension
- Dyspnea on exertion — earliest and most common symptom; progresses to dyspnea at rest
- Fatigue and weakness
- Syncope or pre-syncope — exertional, indicates severe PH
- Chest pain — right ventricular angina, often exertional
- Peripheral edema — sign of right heart failure / cor pulmonale (I27.81)
- Cyanosis — in advanced or shunt-related PH (Eisenmenger syndrome I27.83)
- Loud P2 (pulmonary component of S2) on auscultation; right ventricular heave
- Hemoptysis — uncommon; occurs in CTEPH (I27.24) or idiopathic PAH
- Ascites / hepatomegaly — in advanced cor pulmonale with right ventricular failure
Per ICD-10-CM Official Guidelines I.C.18, when a symptom (e.g., headache, dyspnea) is an integral manifestation of an established diagnosis, code only the diagnosis — not the symptom code. If the symptom is separately documented as a distinct clinical problem requiring additional evaluation, it may be coded additionally.
🧭 Differential Diagnosis
| Condition | Key Distinguishing Features | Primary ICD-10-CM Code |
|---|---|---|
| Essential (primary) hypertension | No identifiable secondary cause; most common; diagnosis of exclusion in adults | I10 |
| White coat hypertension | BP elevated only in clinical setting; normal ambulatory BP monitoring (ABPM); use R03.0 if no formal dx | R03.0 / I10 if dx confirmed |
| Secondary — renovascular | Renal artery stenosis (atherosclerosis or FMD); abdominal bruit; difficult to control | I15.0 |
| Secondary — renal parenchymal | CKD, glomerulonephritis, polycystic kidney disease; elevated creatinine | I15.1 |
| Secondary — endocrine | Primary aldosteronism (hypokalemia, adrenal adenoma), Cushing syndrome, pheochromocytoma (paroxysmal HTN, headache, diaphoresis, tachycardia), thyroid disease | I15.2 |
| Secondary — drug-induced | NSAIDs, oral contraceptives, decongestants, stimulants, cocaine, cyclosporine, erythropoietin | I15.8 |
| Hypertensive urgency (I16.0) | BP ≥180/120; no end-organ damage; asymptomatic or mild symptoms | I16.0 |
| Hypertensive emergency (I16.1) | Provider-documented hypertensive emergency; typically severe BP elevation WITH acute end-organ damage (stroke, AMI, AKI, papilledema, aortic dissection) | I16.1 + specific EOD code(s); sequence based on reason for encounter |
| Idiopathic PAH (Group 1) | No identifiable cause; diagnosis after exclusion of other PH groups; right heart cath shows pre-capillary PH/PAH physiology (mPAP >20 mmHg, PAWP ≤15 mmHg, PVR >2 Wood units) | I27.0 |
| PH due to left heart disease (Group 2) | Most common PH; associated with HF with preserved or reduced EF, mitral/aortic valve disease | I27.22 |
| PH due to lung disease/hypoxia (Group 3) | COPD, ILD, obstructive sleep apnea, chronic hypoxemia; often mild PH | I27.23 |
| CTEPH (Group 4) | History of PE; perfusion scan shows mismatched defects; potentially curable with pulmonary endarterectomy | I27.24 |
| Other/multifactorial PH (Group 5) | Sarcoidosis, chronic hemolytic anemia, myeloproliferative disorders, metabolic diseases | I27.29 |
| Cor pulmonale (chronic) | Right ventricular hypertrophy/failure due to chronic lung disease; distinguish from acute cor pulmonale (I26.0x, which is due to acute PE) | I27.81 |
| Gestational hypertension | New-onset HTN after 20 weeks gestation; no proteinuria; resolves postpartum; code O13.x — NOT I10 | O13.x |
| Preeclampsia | HTN + proteinuria ≥300 mg/24h or end-organ damage after 20 weeks; severe features: BP ≥160/110, thrombocytopenia, AKI, impaired liver function, pulmonary edema, new headache | O14.x |
📋 Clinical Indicators
When a patient has documented hypertension AND a cardiac finding (left ventricular hypertrophy, diastolic dysfunction, systolic heart failure), the medical record should specify the relationship. If the provider’s documentation does not clearly link the conditions, a compliant CDI query may ask: “Based on the documented findings of [hypertension] and [diastolic dysfunction/systolic heart failure/LVH], is there a causal relationship? If yes, is this hypertensive heart disease with or without heart failure? If heart failure is present, please specify type (systolic/diastolic/combined) and acuity (acute/chronic/acute-on-chronic).” Follow ACDIS/AHIMA query guidelines — queries must be non-leading with multiple choice options including clinical indicators.
🦴 Anatomy & Pathophysiology
Systemic Hypertension
Essential hypertension results from a complex interplay of genetic predisposition and environmental factors that increase systemic vascular resistance (SVR). The renin-angiotensin-aldosterone system (RAAS) plays a central role — angiotensin II causes direct vasoconstriction and stimulates aldosterone release, increasing sodium and water retention. Sympathetic nervous system overactivation, endothelial dysfunction, and impaired nitric oxide bioavailability compound the elevated BP.
End-organ damage pathways:
- Heart: Pressure overload causes left ventricular hypertrophy (LVH) → diastolic dysfunction → heart failure with preserved EF (HFpEF). Chronic pressure overload may eventually cause systolic dysfunction (HFrEF). The coronary microcirculation also sustains injury, increasing ischemic risk.
- Kidneys: Hypertension causes glomerular hypertension, progressive nephrosclerosis, and podocyte damage → proteinuria → CKD. Per ICD-10-CM Guidelines I.C.9.a.2, the relationship between HTN and CKD is presumed causal without explicit documentation unless the provider indicates the CKD is not related to the hypertension.
- Brain: Small vessel disease, lacunar infarcts, cerebral microbleeds, and in HTN emergency, cerebral autoregulation failure → hypertensive encephalopathy (I67.4).
- Retina: Arteriovenous nicking, copper-wiring, flame hemorrhages, papilledema (grade IV) — coded as H35.0 with the applicable hypertension code from I10–I15; sequencing is based on the reason for the encounter.
- Aorta: Chronic pressure stress contributes to aortic dissection (I71.x) and aneurysm formation.
Pulmonary Hypertension
In PAH (Group 1), vasoconstriction, smooth muscle proliferation, endothelial dysfunction, and thrombosis in situ narrow the pulmonary arterioles, raising pulmonary vascular resistance (PVR). The right ventricle (RV) initially adapts via hypertrophy, but eventually fails — manifesting as cor pulmonale (I27.81). Key vasoactive imbalances: reduced prostacyclin (vasodilator), reduced nitric oxide, elevated endothelin-1 (potent vasoconstrictor and proliferative agent). Targeted PAH therapies address these pathways (endothelin receptor antagonists, PDE-5 inhibitors, prostacyclin analogues, soluble guanylate cyclase stimulators).
In Groups 2–5, the mechanism differs by etiology: Group 2 PH occurs from elevated pulmonary venous pressure transmitted backward from left-sided cardiac disease; Group 3 from chronic hypoxic vasoconstriction; Group 4 from mechanical obstruction of pulmonary vessels by organized thrombus; Group 5 from miscellaneous mechanisms including extrinsic compression or metabolic derangements.
💊 Medication Impact / Treatment
Antihypertensive Medication Classes (Systemic HTN)
Chronic antihypertensive pharmacotherapy should be documented in the medical record and may be flagged with long-term drug use code Z79.899 (Other long-term drug use). Key classes:
- ACE inhibitors / ARBs — first-line for HTN with CKD/proteinuria and hypertensive HF; renal-protective. E.g., lisinopril, enalapril (ACEi); losartan, valsartan (ARB). ARNI (sacubitril/valsartan) for HFrEF.
- Thiazide / thiazide-like diuretics — hydrochlorothiazide, chlorthalidone; first-line in many guidelines.
- Calcium channel blockers (CCB) — amlodipine; first-line; especially for older adults and isolated systolic HTN.
- Beta-blockers — metoprolol succinate, carvedilol; preferred with hypertensive heart disease/HF; atenolol for rate control.
- Aldosterone antagonists — spironolactone, eplerenone; used in resistant HTN and primary aldosteronism (I15.2).
- Loop diuretics — furosemide (J1940), bumetanide; for volume overload with HTN + HF or CKD stage 4-5.
- Alpha-1 blockers, central agonists (clonidine), direct vasodilators (hydralazine) — adjunctive.
- IV antihypertensives for HTN emergency — nicardipine, labetalol, clevidipine, esmolol, nitroprusside; coded per IV drug administration.
- Epoetin alfa in ESRD — Q4081 (HCPCS); secondary polycythemia can contribute to elevated BP.
PAH-Specific Therapies
PAH requires specialized treatments targeting the pathobiological pathways. Oral agents are generally covered under Medicare Part D; IV/SC/inhaled agents may be covered under Part B or DME:
- Endothelin receptor antagonists (ERAs) — bosentan (Tracleer), ambrisentan (Letairis), macitentan (Opsumit); oral — Part D. Require REMS programs due to hepatotoxicity/teratogenicity risk.
- PDE-5 inhibitors — sildenafil (Revatio), tadalafil (Adcirca); oral — Part D.
- Soluble guanylate cyclase (sGC) stimulators — riociguat (Adempas); oral — Part D. CONTRAINDICATED with PDE-5 inhibitors.
- Prostacyclin analogues / pathway agonists:
- Epoprostenol (Flolan, Veletri) IV continuous — J1325 for epoprostenol drug supply when separately billable; ambulatory infusion pump E0781 may apply for covered external infusion pump use; Part B DME pump rules vary by payer
- Treprostinil SC/IV (Remodulin) — J3285 for treprostinil injection when separately billable; inhaled treprostinil (Tyvaso) — J7686 when covered under nebulizer/DME policy
- Iloprost inhaled (Ventavis) — J3490
- Selexipag (Uptravi) — oral prostacyclin receptor agonist; Part D.
Documentation of specific PAH therapy should prompt CDI review to ensure appropriate PAH group coding (I27.0, I27.21–I27.29) and confirmation that right heart catheterization values are captured in the record.
Riociguat (Adempas) and PDE-5 inhibitors (sildenafil, tadalafil) are absolutely contraindicated together due to risk of severe hypotension. When auditing medication records in PAH patients, flag concurrent use for physician review. This is a black-box warning from the FDA.
Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT procedure coding, HCC v28 risk adjustment mapping, CDI query templates, MS-DRG impact, and a complete audit checklist — all available to CCO Members.
← Back to All Clinical Documentation Guides
📘 ICD-10-CM Guidelines
Guideline I.C.9.a — Hypertension
The FY2026 ICD-10-CM Official Guidelines for Coding and Reporting, Section I.C.9.a, provides the following rules for hypertension:
I.C.9.a.1 — Hypertension with Heart Disease
ICD-10-CM presumes a causal relationship between hypertension and heart involvement and between hypertension and kidney involvement because the conditions are linked by “with” in the Alphabetic Index. Code the conditions as related even without provider documentation explicitly linking them, unless the documentation clearly states they are unrelated. Assign a code from I11.x for hypertension with one or more heart conditions classified to I50.-, I51.4–I51.7, I51.89, or I51.9. Assign I11.0 when heart failure is documented, plus additional code(s) from I50.x to identify the type of heart failure. Assign I11.9 when no heart failure is present.
Per Guideline I.A.15, “The word ‘with’ or ‘in’ should be interpreted to mean ‘associated with’ or ‘due to’ when it appears in a code title, the Alphabetic Index, under a main term, or an instructional note in the Tabular List.” The provider does not need to explicitly document the link when the Alphabetic Index connects two conditions with “with.” However, for hypertension + heart disease, the combination codes exist in the index — coders must follow them when the documentation supports the link.
I.C.9.a.2 — Hypertensive Chronic Kidney Disease
The relationship between hypertension and CKD is presumed causal per ICD-10-CM Guidelines, regardless of whether the provider documents the link, unless the provider indicates the CKD is not related to the hypertension. When a patient has both hypertension and CKD, assign a code from I12.x, with the appropriate N18.x code as an additional code to identify the CKD stage. Do NOT separately code I10 + N18.x when the presumed causal relationship applies. CKD without hypertension uses N18.x alone. Hypertension without CKD uses I10.
I.C.9.a.3 — Hypertensive Heart and Chronic Kidney Disease
When a patient has hypertension, heart disease/heart failure, AND CKD simultaneously, assign the appropriate combination code from I13.x. This is required regardless of whether all three conditions are explicitly linked. Use additional codes for the type of heart failure (I50.x) and CKD stage (N18.x).
I.C.9.a.4 — Secondary Hypertension
Secondary hypertension codes (I15.x) are assigned when an identifiable underlying cause is documented. Two codes are required: one to identify the underlying etiology and one from category I15 to identify the hypertension (e.g., renal artery stenosis I70.1, primary hyperaldosteronism E26.0x, pheochromocytoma D35.0x, Cushing syndrome E24.x). Sequencing is determined by the reason for admission/encounter.
I.C.9.a.10 — Hypertensive Crisis
Assign a code from category I16 for documented hypertensive urgency, hypertensive emergency, or unspecified hypertensive crisis. Code also any identified hypertensive disease (I10–I15, I1A); sequencing is based on the reason for the encounter. If the documentation supports hypertensive emergency and a specific end-organ damage condition (e.g., acute MI I21.x, intracerebral hemorrhage I61.x, AKI N17.x), code the EOD condition as well; I16.1 does not replace the specific EOD code. I.C.9.a.12 — Resistant Hypertension: Assign I1A.0 as an additional code when apparent treatment resistant hypertension, treatment resistant hypertension, or true resistant hypertension is documented by the provider. Sequence the code for the specific type of existing hypertension first, if known.
I.C.9.a.11 — Pulmonary Hypertension Pulmonary hypertension is classified to category I27, Other pulmonary heart diseases. For secondary pulmonary hypertension (I27.1, I27.2-), code also any associated conditions or adverse effects of drugs or toxins. Sequencing is based on the reason for the encounter, except for adverse effects of drugs. I.C.9.a.12 — Hypertension, Resistant Resistant hypertension refers to blood pressure that remains above goal despite antihypertensive medications. Assign I1A.0, Resistant hypertension, as an additional code when apparent treatment resistant hypertension, treatment resistant hypertension, or true resistant hypertension is documented by the provider. Sequence the code for the specific type of existing hypertension first, if known. Guideline I.C.9.b — Atherosclerotic Coronary Artery Disease and Angina
When CAD coexists with HTN, code both separately unless the documentation explicitly links them as part of the same disease process. CAD uses I25.x; hypertension uses I10/I11.x as appropriate.
Pregnancy Hypertension — Guideline I.C.15
During pregnancy, childbirth, and the puerperium, hypertension conditions use codes from Chapter 15 (O00–O9A), NOT codes from Chapter 9 (I00–I99). Pre-existing hypertension complicating pregnancy uses O10.x (by type: essential, secondary, pre-existing heart disease, CKD). Gestational hypertension without proteinuria uses O13.x. Gestational hypertension with proteinuria (preeclampsia) uses O14.x. Eclampsia uses O15.x.
Pediatric and Neonatal Pulmonary Hypertension — Guideline I.C.16
Persistent pulmonary hypertension of the newborn (PPHN) is coded P29.3. This condition reflects failure of the normal circulatory transition at birth, with high pulmonary vascular resistance and right-to-left shunting. It is distinct from PAH in adults and does not use I27.x codes.
HTN Coding Algorithm
- Elevated BP at visit, no HTN diagnosis: → R03.0 only; do not infer HTN diagnosis
- HTN documented, no complications: → I10
- HTN + documented heart disease/HF: → I11.0 (with HF) + I50.x type; or I11.9 (without HF)
- HTN + CKD of any stage: → Presume causal → I12.x + N18.x stage (do not use I10 + N18.x)
- HTN + HF + CKD: → I13.x + N18.x + I50.x
- Secondary HTN with identifiable cause: → I15.x + underlying cause code
- BP ≥180/120: → I16.0 (urgency, no EOD) or I16.1 (emergency, with EOD) + EOD codes
- Pregnancy + HTN: → O10.x–O16.x (NOT I10)
- Coding I10 + N18.x separately instead of I12.x — automatic presumption of causal link is missed
- Omitting I50.x type when I11.0 or I13.0/I13.2 is coded — combination code requires additional HF type
- Using I10 during pregnancy instead of O10.x–O16.x
- Coding HTN urgency (I16.0) when documentation supports emergency (I16.1) — EOD evidence in record not coded
- Coding I27.20 (PH unspecified) when group classification is documented — query for group increases RAF and clinical specificity
- Omitting N18.x stage code when coding I12.x or I13.x — stage always required as additional code
🔢 ICD-10-CM Code Set (Tabular)
Systemic Hypertension — I10–I16
| Code | Description | Notes / Coding Tips |
|---|---|---|
| I10 | Essential (primary) hypertension | Use when no documented hypertensive complication. No HCC v28 alone. Not mapped in V24 or V28. Most frequently coded diagnosis in the US. |
| I11.0 | Hypertensive heart disease with heart failure | Must add I50.x for type of HF. Maps to HCC 226 in V28; the I50.- code may map to HCC 222, 224, or 225. |
| I11.9 | Hypertensive heart disease without heart failure | No HCC v28 alone. Use when cardiac manifestation (LVH, etc.) documented but no HF. |
| I12.0 | Hypertensive CKD with CKD stage 5 or end-stage renal disease | Add N18.5 (stage 5) or N18.6 (ESRD). HCC 326 (N18.5 and N18.6 also map to HCC 326). |
| I12.9 | Hypertensive CKD with CKD stages 1–4 or unspecified | Add N18.1–N18.4 or N18.9. I12.9 has no HCC; N18.4 → 327, N18.32 → 328, N18.30/N18.31 → 329. |
| I13.0 | Hypertensive heart and chronic kidney disease with heart failure and CKD stages 1–4 or unspecified CKD | Add N18.x stage + I50.x HF type. I13.0 maps to HCC 226; the CKD stage code adds its own HCC (327–329). |
| I13.10 | Hypertensive heart and chronic kidney disease without heart failure, with CKD stages 1–4 or unspecified CKD | No HF present. Add N18.x. I13.10 has no HCC; the CKD stage code maps by stage (327–329). |
| I13.11 | Hypertensive heart and chronic kidney disease without heart failure, with CKD stage 5 or ESRD | CKD stage 5/ESRD without HF. Add N18.5 or N18.6. HCC 326. |
| I13.2 | Hypertensive heart and chronic kidney disease with heart failure and CKD stage 5 or ESRD | All three: HTN + HF + ESRD. Add N18.5/N18.6 + I50.x HF type. HCC 226 + 326. |
| I15.0 | Renovascular hypertension | Due to renal artery stenosis (atherosclerosis I70.1 or FMD Q27.1x). Code underlying cause additionally. |
| I15.1 | Hypertension secondary to other renal disorders | CKD as cause (distinct from HTN causing CKD, which is I12.x). Glomerulonephritis, polycystic kidney. Add underlying renal dx. |
| I15.2 | Hypertension secondary to endocrine disorders | Cushing (E24.x), primary aldosteronism (E26.x), pheochromocytoma (D35.0x / C74.1x). Add the endocrine dx. |
| I15.8 | Other secondary hypertension | Drug-induced (add T-code for drug), sleep apnea-induced, coarctation of aorta. |
| I15.9 | Secondary hypertension, unspecified | Use only when secondary HTN confirmed but cause unidentifiable; query for specificity. |
| I16.0 | Hypertensive urgency | BP ≥180/120 mmHg without end-organ damage. New FY2018 code. No HCC. |
| I16.1 | Hypertensive emergency | BP ≥180/120 WITH end-organ damage (AMI, ICH, AKI, papilledema, aortic dissection). Code EOD additionally. No standalone HCC. |
| I16.9 | Hypertensive crisis, unspecified | Use only when urgency/emergency is not documented; query for specificity. |
| I1A.0 | Resistant hypertension | Additional code for apparent treatment resistant hypertension, treatment resistant hypertension, or true resistant hypertension. Sequence the specific type of existing hypertension first, if known. |
| I97.3 | Postprocedural hypertension | Use when postoperative/postprocedural hypertension is documented as a complication of a procedure. |
| I67.4 | Hypertensive encephalopathy | Distinct from I16.1; represents cerebral manifestation. Use with I10/I11.x as applicable. |
| H35.0 | Background retinopathy and retinal vascular changes (incl. hypertensive retinopathy) | Use H35.0 along with the applicable hypertension code from I10–I15; sequencing is based on the reason for the encounter. |
Pulmonary Hypertension — I27.x
| Code | Description | WHO Group / Notes |
|---|---|---|
| I27.0 | Primary pulmonary hypertension | Group 1 — Idiopathic PAH (IPAH); no identifiable cause. HCC 226 v28. |
| I27.1 | Kyphoscoliotic heart disease | Pulmonary heart disease due to kyphoscoliosis; distinct from other PH groups. |
| I27.20 | Pulmonary hypertension, unspecified | Use when type/group not documented; query for specificity. HCC 226 v28. |
| I27.21 | Secondary pulmonary arterial hypertension | Group 1′ — Heritable PAH, CTD-associated (scleroderma, MCTD, SLE), drug/toxin-induced, HIV-associated, portopulmonary, CHD-associated. HCC 226. |
| I27.22 | Pulmonary hypertension due to left heart disease | Group 2 — Most common cause of PH; due to HFpEF, HFrEF, mitral/aortic valve disease. Add I50.x or valvular code. HCC 226. |
| I27.23 | Pulmonary hypertension due to lung diseases and hypoxia | Group 3 — COPD (J44.x), ILD (J84.x), OSA (G47.33), chronic hypoxia. Add lung disease code. HCC 226; COPD maps separately (HCC 280). |
| I27.24 | Chronic thromboembolic pulmonary hypertension | Group 4 — CTEPH; prior PE with incomplete resolution; treated with PEA surgery, riociguat, balloon PTA. Add I27.82 (HCC 267). HCC 226. |
| I27.29 | Other secondary pulmonary hypertension | Group 5 — Multifactorial/unclear: sarcoidosis, PVOD, chronic hemolytic anemia, metabolic, compression. HCC 226. |
| I27.81 | Cor pulmonale (chronic) | RVH/RV failure due to chronic lung disease. HCC 226. Distinct from acute cor pulmonale I26.01-I26.09. |
| I27.82 | Chronic pulmonary embolism | Requires prior PE; use with I27.24 for CTEPH. HCC 267. See PE CDG. |
| I27.83 | Eisenmenger’s syndrome | Congenital heart defect with reversed shunt and severe PH; link to Congenital Heart CDG. HCC 226. |
| I27.89 | Other specified pulmonary heart diseases | Pulmonary vascular disease NOS, pulmonary arteritis. HCC 226. |
| I27.9 | Pulmonary heart disease, unspecified | Use only when no specificity available; query for group. HCC 226. |
Pregnancy-Related Hypertension Codes
| Code Range | Description | Notes |
|---|---|---|
| O10.x | Pre-existing hypertension complicating pregnancy, childbirth, puerperium | HTN diagnosed before pregnancy or <20 weeks gestation. Subclassified by: .0 essential HTN, .1 pre-existing HTN heart disease, .2 pre-existing HTN CKD, .3 both, .4 secondary HTN, .9 unspecified; further specified by trimester/puerperium. See Pregnancy CDG. |
| O11.x | Pre-existing HTN with pre-eclampsia | By trimester/puerperium. |
| O12.x | Gestational edema and proteinuria without HTN | Edema with or without proteinuria but no HTN dx. |
| O13.x | Gestational HTN (induced) without significant proteinuria | New-onset after 20 weeks; no proteinuria; by trimester/puerperium. |
| O14.x | Gestational HTN with proteinuria (preeclampsia) | O14.0 mild, O14.1 severe, O14.2 HELLP, O14.9 unspec; by trimester/puerperium. |
| O15.x | Eclampsia | In pregnancy, delivery, puerperium; with/without HF. |
| O16.x | Unspecified maternal hypertension | By trimester/puerperium; use only when type undocumented. |
Neonatal/Pediatric Codes
| Code | Description | Notes |
|---|---|---|
| P29.3 | Persistent pulmonary hypertension of newborn (PPHN) | Failure of normal circulatory transition; high PVR with right-to-left shunting; treated with iNO, ECMO. |
| P29.4 | Transient myocardial ischemia in newborn | Perinatal myocardial injury; may coexist with PPHN. |
| P29.8 | Other cardiovascular disorders originating in perinatal period | Includes other neonatal cardiac conditions not elsewhere classified. |
| P22.8 | Other respiratory distress of newborn | May include secondary PPHN from respiratory causes. |
Frequently Associated Comorbidity Codes
| Code | Description | Relevance to HTN/PH |
|---|---|---|
| I50.x | Heart failure (by type) | Always add when coding I11.0, I13.0, I13.2 — required as additional code |
| N18.x | CKD stage 1–5, ESRD (N18.1–N18.6, N18.9) | Always add when coding I12.x or I13.x — required as additional code. See Renal CDG. |
| R03.0 | Elevated BP reading without HTN diagnosis | Use when BP elevated at visit but no documented HTN diagnosis |
| G47.33 | Obstructive sleep apnea (adult) | Common comorbidity; OSA contributes to resistant HTN and Group 3 PH |
| E66.01 / E66.811–E66.813 | Obesity (morbid, severe) | Major HTN risk factor and comorbidity; E66.01 and E66.813 map to HCC 48; E66.811 and E66.812 do not. See Obesity CDG. |
| E11.x | Type 2 diabetes mellitus | Common comorbidity with HTN; DM + HTN often = CKD triad. See DM CDG. |
| F17.2xx | Nicotine dependence | Major cardiovascular risk factor; document and code per Guidelines |
| Z79.899 | Other long-term drug use (antihypertensives) | Document long-term antihypertensive therapy |
| Z86.79 | Personal history — other circulatory system diseases | Prior HTN-related events not currently active |
| R93.1 | Abnormal findings on diagnostic imaging of heart | Abnormal echo/cardiac imaging without specific diagnosis |
| N25.81 | Secondary hyperparathyroidism of renal origin | Complication of CKD in hypertensive CKD patients |
🔎 Indexing
Key alphabetic index entries in ICD-10-CM FY 2027 for hypertension and pulmonary hypertension:
| Index Lookup Term | Leads To | Code |
|---|---|---|
| Hypertension, hypertensive (arterial) (benign) (essential) | Main entry | I10 |
| Hypertension, with heart disease / heart failure | Combination entry — I11.x | I11.0 (with HF), I11.9 (without HF) |
| Hypertension, with chronic kidney disease | Combination entry — I12.x, by stage | I12.0 (stage 5/ESRD), I12.9 (stages 1-4) |
| Hypertension, with heart disease and chronic kidney disease | I13.x by HF + CKD stage | I13.0, I13.10, I13.11, I13.2 |
| Hypertension, secondary | I15.x by cause | I15.0–I15.9 |
| Hypertension, renovascular | Direct entry | I15.0 |
| Hypertension, due to endocrine disorder | I15.2 | I15.2 |
| Hypertensive crisis | I16.x | I16.0 urgency, I16.1 emergency, I16.9 unspec |
| Hypertension, resistant | I1A.0 | Additional code for apparent treatment resistant hypertension, treatment resistant hypertension, or true resistant hypertension |
| Hypertension, pulmonary (arterial) (idiopathic) (primary) | I27.0 | I27.0 |
| Hypertension, pulmonary, secondary | I27.21–I27.29 by type | I27.21–I27.29 |
| Hypertension, pulmonary, due to left heart disease | I27.22 | I27.22 |
| Hypertension, pulmonary, thromboembolic (chronic) | I27.24 | I27.24 |
| Cor pulmonale (chronic) | I27.81 | I27.81 |
| Cor pulmonale (acute) | I26.09 | I26.09 (with acute PE) |
| Hypertension, gestational | O13.x | O13.x by trimester |
| Pre-eclampsia | O14.x | O14.0/O14.1/O14.2/O14.9 |
| Eclampsia | O15.x | O15.0–O15.9 |
| Blood pressure, elevated | R03.0 | R03.0 |
| Retinopathy, hypertensive | H35.0 (code first HTN) | I10 first, then H35.0 |
| Encephalopathy, hypertensive | I67.4 | I67.4 |
🏥 CPT
The following CY2027 CPT codes are commonly associated with hypertension diagnosis, monitoring, and management, as well as pulmonary hypertension workup and treatment.
| CPT Code | Description | Typical Use | Notes |
|---|---|---|---|
| 93784 | Ambulatory BP monitoring (ABPM), 24-hour with physician review/analysis | Confirms white-coat vs. true HTN; masked HTN | Also 93786 (recording only), 93788 (scanning analysis), 93790 (physician review only). For Medicare ABPM billing, verify current payer-specific rules and coverage limits. |
| 93786 | ABPM, recording only | Technical component of ABPM | Paired with 93790 or 93788 |
| 93788 | ABPM, scanning analysis with report | Technical + summary | |
| 93790 | ABPM, review with physician report/interpretation | Physician component | |
| 93000 | Electrocardiogram, routine 12-lead with interpretation | LVH evaluation, arrhythmia screen in HTN | 93005 tracing only; 93010 interpretation only |
| 93040 | Rhythm EKG, 1–3 leads | Rate/rhythm check in HTN management | 93041 tracing, 93042 interpretation |
| 93306 | Echocardiography, transthoracic, complete (M-mode, 2D, Doppler) | LVH assessment, EF, valvular evaluation in HTN; PAH diagnosis | Most important test for HTN cardiac evaluation. 93307 limited, 93308 follow-up. |
| 93350 | Stress echocardiography (exercise or pharmacologic), complete | Ischemic evaluation, HFpEF stress testing | 93351 with supervision |
| 93224 | Continuous EKG monitoring (Holter), 48 hours, with analysis and interpretation | Arrhythmia evaluation in hypertensive patients | 93225 recording, 93226 scanning, 93227 review/interpretation. 93224–93227 series. |
| 93228 | External EKG rhythm derivation with continuous monitoring, 2–14 days | Extended rhythm monitoring in HTN patients | 93229 physician interpretation; 93268–93272 event monitor codes. |
| 93270 | Wearable mobile cardiac telemetry, heart rhythm, includes analysis 30 days | Remote cardiac monitoring | 93271 recording, 93272 analysis/interpretation |
| 93452 | Left heart catheterization (LHC) | Coronary and LV pressure measurement; HTN-related CAD workup | 93458/93459/93460/93461/93462 include coronary/LV angiography combinations |
| 93530 | Right heart catheterization (RHC), for congenital cardiac anomalies | RHC in complex congenital PH (Eisenmenger) | 93531–93533 RHC with LHC combinations. Gold standard for PAH: measure mPAP, PCWP, PVR. |
| 93451 | Right heart catheterization (adult/acquired heart disease) | Gold standard PAH diagnosis: mPAP ≥20 mmHg at rest, PCWP ≤15 mmHg (Group 1) | Vasodilator challenge (adenosine/iNO) performed during RHC for PAH reversibility testing |
| 93563 | Injection procedure for selective pulmonary arteriogram | PAH evaluation: pulmonary angiography for CTEPH diagnosis | Performed during RHC or separate catheterization |
| 71260 | CT thorax with contrast | PAH workup: mediastinal adenopathy, pulmonary fibrosis, CTEPH (filling defects) | 71275 CT angiography thorax |
| 76770 | Retroperitoneum ultrasound, complete | Renal artery evaluation for renovascular HTN | 76775 limited retroperitoneum US; renal duplex Doppler 93975/93976 |
| 80053 | Comprehensive metabolic panel | Baseline and monitoring: creatinine, BUN, Na, K, glucose, LFTs for HTN management | Includes 82565 creatinine, 84132 potassium, 84295 sodium, 84520 BUN, 82040 albumin |
| 84484 | Troponin, quantitative | End-organ damage (AMI) in HTN emergency (I16.1) | Add 83605 lactate for EOD severity assessment |
| 83605 | Lactate | Shock/end-organ failure assessment in HTN emergency | |
| 99490 | Chronic care management (CCM), 20 minutes/month, complex chronic conditions | Ongoing HTN management in outpatient setting | 99439 additional 20 min; 99491/99437 provider-performed CCM |
| 99424 / +99425 | Principal care management (PCM), physician/QHP personally provided; first 30 min / each additional 30 min per calendar month | Single high-risk condition management for complex HTN with significant risk and frequent medication or care-plan adjustments | Use 99425 only with 99424. Clinical staff PCM uses 99426 first 30 min and +99427 each additional 30 min, directed by physician/QHP. |
| 93793 | Anticoagulant management (INR), outpatient | HTN patients on warfarin for afib, VTE, or valve disease | |
| 93797 | Cardiac rehabilitation, per session (without monitoring) | Post-HTN complications (post-MI, post-HF) | 93798 with monitoring |
Right heart catheterization (93451) is the gold standard for PAH diagnosis per international PAH guidelines. Diagnosis requires mPAP >20 mmHg at rest with pulmonary capillary wedge pressure (PCWP/PAWP) ≤15 mmHg and PVR >2 Wood units (for Group 1 PAH). When RHC results appear in the record showing mPAP >20 mmHg, ensure a specific I27.x code (not just I27.20) is captured in the problem list and discharge summary.
🧾 HCPCS
| HCPCS Code | Description | Typical Use in HTN/PH |
|---|---|---|
| J1940 | Furosemide injection, 20 mg | IV loop diuretic for volume overload in HTN with HF or CKD; acute decompensated HF |
| J1325 / J3285 / J7686 / Q4074 | PAH prostacyclin-pathway drug supply codes | Epoprostenol injection (J1325), treprostinil injection (J3285), treprostinil inhalation solution (J7686), and iloprost inhalation solution (Q4074) have specific HCPCS codes when payer coverage and billing circumstances support separate reporting. Use J3490 only when no specific HCPCS code applies and payer policy supports an unclassified drug code. |
| J7999 | Compounded drug, not otherwise classified | Compounded preparations for PAH infusion management |
| J1642 | Heparin sodium, per 10 units | Anticoagulation in CTEPH; central line maintenance in PAH infusion patients |
| J1650 | Enoxaparin sodium, 10 mg | Anticoagulation in HTN patients with afib, VTE, or CTEPH (I27.24) |
| Q4081 | Epoetin alfa injection, 100 units (ESRD use) | Anemia of CKD in hypertensive CKD/ESRD patients; Part B ESRD facility or non-ESRD physician office |
| E0781 | Ambulatory infusion pump, single or multiple channels, per day | Continuous IV/SC prostacyclin infusion (epoprostenol, treprostinil) — DME Part B; essential for PAH treatment |
| E1390 | Oxygen concentrator, single delivery port, 85% or greater concentration at rest | Stationary home O2 for chronic hypoxic PH (Group 3) or severe PAH; requires SpO2 documentation |
| E0434 | Portable liquid oxygen system, rental, including portable container, supply of liquid oxygen, tubing, flow regulator, etc. | Portable O2 for ambulatory PH patients |
| E0435 | Portable liquid oxygen contents, per unit | Refill for portable liquid O2 |
| E0601 | Continuous airway pressure (CPAP) device | OSA comorbidity with HTN/PH (G47.33); treatment of OSA reduces BP and PH Group 3 contribution |
| J0270 | Alprostadil injection, 1.25 mcg | Neonatal ductal patency for ductal-dependent congenital heart disease/PH physiology; not adult PAH therapy and not routine PPHN management. Verify payer and NDC-specific billing. |
| J0500–J0550 | Dicyclomine / Atropine (older coding) | Not HTN-specific; included for awareness — do not confuse with antihypertensive J-codes |
| J3380 | Not PAH related | Vedolizumab — GI biologic; listed for avoidance; not a PAH code |
| Note: Oral PAH agents | Sildenafil (Revatio), tadalafil (Adcirca), bosentan (Tracleer), ambrisentan, macitentan, riociguat, selexipag | Oral agents covered under Medicare Part D (not Part B); no HCPCS J-code for Part B. Verify formulary tier for prior authorization. |
📚 AHA Coding Clinic
The following guidance from the AHA Coding Clinic for ICD-10-CM/PCS is relevant to hypertension and pulmonary hypertension coding:
| Topic | Guidance Summary | Source |
|---|---|---|
| HTN + CKD Presumed Causality | Section I.C.9.a.2 presumes a causal relationship between hypertension and CKD: assign a code from category I12 when both are present, with a code from category N18 to identify the stage of CKD. CKD should not be coded as hypertensive if the provider indicates the CKD is not related to the hypertension. Coding Clinic, 4Q 2018: when the provider documents type 2 diabetes with CKD and the patient also has hypertension, assign E11.22, I12.9, and N18.9, because the classification presumes both relationships. Coding Clinic, 3Q 2019: when the provider documents CKD due to diabetes, diabetic CKD, diabetic nephropathy, or similar terminology, a causal relationship is indicated and denotes the CKD is not related to the hypertension; assign the diabetic CKD code, code the hypertension separately rather than as hypertensive CKD, and do not assign both E11.21 and E11.22. | Centers for Medicare & Medicaid Services and National Center for Health Statistics. ICD-10-CM Official Guidelines for Coding and Reporting FY 2027, Section I.C.9.a.2; AHA Coding Clinic, 4Q 2018, “Hypertension, Diabetes Mellitus and Chronic Kidney Disease“; AHA Coding Clinic, 3Q 2019, “Hypertension with Diabetic Nephropathy and Chronic Kidney Disease“ |
| I10 Removed from HCC v28 | CMS removed I10 from HCC mapping in v28 risk adjustment model. I10 alone no longer generates RAF credit. Downstream complications must be coded with specificity (I11.x, I12.x, I13.x + N18.x + I50.x). | CMS v28 Announcement 2023; CMS Risk Adjustment |
| Hypertensive Urgency and Emergency Codes | I16.0 (hypertensive urgency), I16.1 (hypertensive emergency), and I16.9 (hypertensive crisis, unspecified) were created effective October 1, 2016 (FY 2017), as described in Coding Clinic, 4Q 2016. Section I.C.9.a.10 directs a code from category I16 for documented hypertensive urgency, emergency, or crisis, and to code also the hypertensive disease (I10-I15, I1A); sequencing is based on the reason for the encounter. In the Coding Clinic example, the end-organ condition (I61.0) is sequenced first, followed by I16.1 and I10. Accelerated or malignant hypertension without documentation of crisis is assigned I10. | AHA Coding Clinic, 4Q 2016, “Hypertensive Crisis, Urgency and Emergency“; Centers for Medicare & Medicaid Services and National Center for Health Statistics. ICD-10-CM Official Guidelines for Coding and Reporting FY 2027, Section I.C.9.a.10 |
| PAH Group Coding Post-2020 ICD-10 Expansion | The I27.2- expansion, effective October 1, 2017 (FY 2018) and described in Coding Clinic, 4Q 2017, classifies pulmonary hypertension by group: I27.21 (secondary pulmonary arterial hypertension, group 1), I27.22 (group 2, due to left heart disease), I27.23 (group 3, due to lung disease and/or hypoxia), I27.24 (group 4, chronic thromboembolic), and I27.29 (group 5, other secondary). I27.0 remains primary pulmonary hypertension. Assign I27.20, Pulmonary hypertension, unspecified, when the type is not documented. Follow the code also notes for associated conditions and adverse effects (Section I.C.9.a.11). | AHA Coding Clinic, 4Q 2017, “Pulmonary Hypertension“; Centers for Medicare & Medicaid Services and National Center for Health Statistics. ICD-10-CM Official Guidelines for Coding and Reporting FY 2027, Section I.C.9.a.11 |
| Cor Pulmonale: Acute vs. Chronic | I27.81, Cor pulmonale (chronic), includes cor pulmonale NOS, has a code also note for right heart failure (I50.81-), and has an Excludes1 note for acute cor pulmonale (I26.0-). Acute cor pulmonale NOS is an inclusion term at I26.09, Other pulmonary embolism with acute cor pulmonale. Coding Clinic, 4Q 2014, advised that I26.09 is not appropriate for acute cor pulmonale due to pulmonary hypertension without pulmonary embolism; that advice predates the I27.2- and I50.81- expansions. | Centers for Medicare & Medicaid Services and National Center for Health Statistics. ICD-10-CM Tabular List of Diseases and Injuries FY 2027, codes I27.81 and I26.09; AHA Coding Clinic, 4Q 2014, “Acute Cor Pulmonale due to Pulmonary Hypertension without Mention of Pulmonary Embolus“ |
| Hypertensive Retinopathy Sequencing | When hypertensive retinopathy is documented, assign H35.0 along with the applicable hypertension code from I10–I15. Sequencing is based on the reason for the encounter. | ICD-10-CM Official Guidelines I.C.9.a.5; ICD-10-CM Tabular List |
| Pregnancy and Pre-existing HTN | Chronic hypertension in pregnancy is pre-existing hypertension and is coded to category O10 (Coding Clinic, 2Q 2025); assign O10.91- when the type of pre-existing hypertension is not specified. O10.0- includes any condition in I10 specified as a reason for obstetric care, so I10 is not added. For pre-existing hypertensive heart disease (O10.1-) or hypertensive CKD (O10.2-), add a secondary code from the appropriate hypertension category (I11 or I12) to specify the type of heart failure or CKD (Section I.C.15.d). Select the O10 code for the episode: pregnancy by trimester, childbirth, or the puerperium. | AHA Coding Clinic, 2Q 2025, “Chronic Hypertension in Pregnancy“; Centers for Medicare & Medicaid Services and National Center for Health Statistics. ICD-10-CM Official Guidelines for Coding and Reporting FY 2027, Section I.C.15.d |
| CTEPH Coding (I27.24 + I27.82) | Chronic thromboembolic pulmonary hypertension (group 4) is assigned I27.24 (Coding Clinic, 4Q 2017). I27.24 has a code also note for associated pulmonary embolism, if applicable (I26.-, I27.82), so report I27.82, Chronic pulmonary embolism, when the provider documents it. I27.82 has a use additional code note for long term (current) use of anticoagulants, if applicable (Z79.01), and an Excludes1 note for personal history of pulmonary embolism (Z86.711). | AHA Coding Clinic, 4Q 2017, “Pulmonary Hypertension“; Centers for Medicare & Medicaid Services and National Center for Health Statistics. ICD-10-CM Tabular List of Diseases and Injuries FY 2027, codes I27.24 and I27.82 |
| Hypertension Associated with Diabetes, with CKD (I15.2, not I12) | When the provider documents hypertension associated with or due to diabetes and the patient has CKD not linked to another condition, assign E11.65 (if hyperglycemia), E11.59, E11.22, I15.2, and the N18 stage code. Do not assign I12: category I12 has an Excludes1 note for I15, and when an Excludes1 note applies only the code it references is assigned (Coding Clinic, 4Q 2018, page 87). | AHA Coding Clinic, 2Q 2026, “Chronic Kidney Disease in a Patient with Hypertension Associated with Diabetes” |
💰 HCC / Risk Adjustment
Hypertension itself does not map to a V28 payment HCC; its combination codes and the required additional codes carry the risk. Mappings below follow the 2024 CMS-HCC model (commonly called V28), which CMS uses at 100 percent for non-PACE Medicare Advantage risk scores and continued for CY 2027, and the CMS 2027 Initial ICD-10-CM Mappings. Coefficients vary by enrollee segment and payer, so this guide does not quote RAF weights; check the current CMS model software. Hierarchies are applied by CMS after coding: code every documented, supported condition.
| ICD-10-CM Code(s) | Description | V28 HCC | Coding / Documentation Notes |
|---|---|---|---|
| I10 | Essential hypertension | No V28 payment HCC | I10 has not mapped to a CMS-HCC payment HCC in V24 or V28 (V24 HCC 85 was heart failure) |
| I11.0 | Hypertensive heart disease with HF | HCC 226 | Also code the HF type (I50.-); the HF code may move the HCC to 222, 224, or 225 |
| I11.9 | Hypertensive heart disease without HF | No V28 payment HCC | — |
| I12.0 | Hypertensive CKD with stage 5 CKD or ESRD | HCC 326 — CKD, Stage 5 | Also code N18.5 or N18.6 (also HCC 326) |
| I12.9 | Hypertensive CKD with stage 1–4 or unspecified CKD | No V28 payment HCC | The N18 stage code carries the HCC: N18.4 → 327; N18.32 → 328; N18.30, N18.31 → 329; N18.1, N18.2, N18.9 → none |
| I13.0 | Hypertensive heart and CKD with HF and stage 1–4 CKD | HCC 226 | Also code the HF type and the CKD stage |
| I13.10 | Hypertensive heart and CKD without HF, stage 1–4 CKD | No V28 payment HCC | Code the CKD stage |
| I13.11 | Hypertensive heart and CKD without HF, stage 5 CKD/ESRD | HCC 326 | Also code N18.5 or N18.6 |
| I13.2 | Hypertensive heart and CKD with HF and stage 5 CKD/ESRD | HCC 226 and HCC 326 | Also code the HF type and N18.5 or N18.6 |
| I15.-, I16.-, I1A.0 | Secondary hypertension; hypertensive crisis; resistant hypertension | No V28 payment HCC | The underlying cause or end-organ damage may map separately |
| I27.0, I27.20–I27.29, I27.9 | Primary and secondary pulmonary hypertension (all groups) | HCC 226 | For secondary PH, code also the associated condition (Guideline I.C.9.a.11); COPD maps separately (HCC 280) |
| I27.81, I27.83, I27.89 | Chronic cor pulmonale; Eisenmenger syndrome; other pulmonary heart disease | HCC 226 | Shares HCC 226 with chronic HF |
| I27.82 | Chronic pulmonary embolism | HCC 267 | Add when the provider documents chronic PE; CTEPH (I27.24) is HCC 226 |
Hypertensive emergency end-organ damage: acute MI (I21.-) → HCC 228; ischemic stroke (I63.-) → HCC 249; intracranial hemorrhage (I60–I62) → HCC 248; aortic dissection (I71.0-) → HCC 264.
When the record shows hypertension, heart failure, and CKD coded as I10 + I50.- + N18.-, this is a coding error to correct, not a query. FY 2027 Guideline I.C.9.a presumes the causal relationship; assign I13.- with the HF type and CKD stage. Query only when the provider has stated the conditions are unrelated or the documentation conflicts, and use a compliant, non-leading query.
Sources: CMS 2027 Initial ICD-10-CM Mappings (2024 CMS-HCC model, V28); CMS CY 2024 Rate Announcement, Attachment VI (hierarchies, constraints, interactions); FY 2027 ICD-10-CM Tabular List, Index, and Official Guidelines Section I.C.9. Verified November 3, 2026.
✍️ CDI Query Templates
All queries below are formatted per ACDIS/AHIMA compliant query standards: non-leading, multiple choice, include clinical indicators, identify impact on coding. CDI specialists should use these templates as frameworks, customizing with patient-specific clinical indicators.
| Clinical Scenario | Query Wording (Framework) | Code Impact |
|---|---|---|
| HTN documented; heart involvement/HF documented but type, acuity, or unrelated cause is unclear | “The record documents hypertension and [heart failure / LVH / cardiomegaly / other heart condition]. ICD-10-CM presumes specified heart involvement is related to hypertension unless the provider documents the conditions are unrelated. Please clarify the heart condition and, if heart failure is present, specify type (systolic, diastolic, combined, right heart, other) and acuity (acute, chronic, acute-on-chronic), or document if the heart condition is unrelated to hypertension.” | I11.0 + I50.x when HF present; I11.9 without HF; code separately only if documented as unrelated |
| HTN + CKD documented; coded separately as I10 + N18.x | “The patient has documented hypertension and CKD stage [X]. Per ICD-10-CM guidelines, these conditions are presumed causally related. Please confirm whether the CKD is related to or associated with the patient’s hypertension, or if the CKD is independently caused by another condition (e.g., diabetic nephropathy, glomerulonephritis): (A) Hypertensive CKD (hypertension is a contributing factor); (B) CKD due to another specified cause — please specify; (C) Cannot be determined.” | I12.x + N18.x (correct) vs. I10 + N18.x (error); the N18 stage code carries the CKD HCC (326–329) |
| HTN + HF + CKD documented; coded as I11.0 + N18.x (missing I13.x combination) | “This patient has documented hypertension, [HF type], and CKD stage [X]. Is there a single disease process linking all three conditions? If so, please document: (A) Hypertensive heart and CKD with heart failure [add CKD stage]; (B) Conditions are separate/unrelated; (C) Cannot determine.” | I13.0 → HCC 226 plus the CKD stage HCC; I13.2 → HCC 226 + HCC 326 |
| BP ≥180/120 documented; unclear if end-organ damage present | “The patient presented with blood pressure of [X/X] mmHg. Please clarify the clinical assessment: (A) Hypertensive urgency — severely elevated BP without end-organ damage; (B) Hypertensive emergency — severely elevated BP WITH end-organ damage — specify: [check all that apply] AKI, AMI, stroke/TIA, hypertensive encephalopathy, aortic dissection, papilledema; (C) Neither — specify alternative diagnosis; (D) Cannot determine.” | I16.0 (urgency, no HCC) vs. I16.1 (emergency) + EOD codes (HCC varies) |
| Pulmonary hypertension documented; group/etiology not specified | “The patient has documented pulmonary hypertension with [RHC showing mPAP X mmHg / echocardiographic findings]. Based on the clinical workup, please classify the pulmonary hypertension: (A) Primary/idiopathic PAH (Group 1 — no identifiable cause); (B) Secondary PAH associated with [CTD/drug/HIV/portal HTN] (Group 1′); (C) PH due to left heart disease — specify type [HFrEF/HFpEF/valvular] (Group 2); (D) PH due to lung disease/hypoxia — specify [COPD/ILD/OSA] (Group 3); (E) Chronic thromboembolic PH — CTEPH (Group 4); (F) Multifactorial/other (Group 5); (G) Cannot determine.” | I27.0–I27.29 specific → HCC 226; I27.81 if cor pulmonale → HCC 226 |
| Cor pulmonale documented; acute vs. chronic distinction unclear | “Cor pulmonale is documented in this patient. Please clarify: (A) Chronic cor pulmonale — right ventricular hypertrophy/failure due to chronic lung disease (specify: COPD, ILD, other); (B) Acute cor pulmonale — acute right heart strain/failure in the context of acute pulmonary embolism; (C) Cannot determine.” | I27.81 (chronic, HCC 226) vs. I26.0x (acute PE with acute cor pulmonale, HCC 267) |
| Secondary HTN suspected (resistant HTN, endocrine findings, renal artery stenosis on imaging) | “This patient has hypertension noted to be difficult to control / with findings suggesting [aldosteronism / pheochromocytoma / renal artery stenosis / Cushing syndrome]. Is the hypertension: (A) Essential/primary hypertension; (B) Secondary hypertension due to renovascular cause (renal artery stenosis); (C) Secondary hypertension due to endocrine cause — specify: primary aldosteronism, pheochromocytoma, Cushing syndrome, other; (D) Secondary hypertension due to another cause — specify; (E) Cannot determine.” | I15.x + underlying cause → endocrine HCC if applicable; I10 if primary |
| Hypertension in pregnant patient coded as I10 | “This patient is pregnant (currently [X] weeks gestation). The hypertension documented should be classified for the obstetric record: (A) Pre-existing hypertension (diagnosed before pregnancy or <20 weeks) — specify type: essential, secondary, with heart disease, with CKD; (B) Gestational hypertension (new onset ≥20 weeks, without proteinuria); (C) Pre-eclampsia (new onset ≥20 weeks WITH proteinuria or end-organ manifestations) — specify: mild, severe, HELLP; (D) Eclampsia; (E) Cannot determine.” | O10.x–O16.x (not I10) — required for compliance per Guidelines I.C.15 |
🧑⚕️ Treatments (Clinical)
Systemic Hypertension — Treatment Overview
Hypertension treatment follows a stepwise approach per the AHA/ACC 2017 Hypertension Guidelines:
- Lifestyle modification (first-line for all stages): DASH diet, sodium restriction (<2.3 g/day), weight loss, increased physical activity, moderation of alcohol, smoking cessation. Addresses F17.2xx, E66.x, and E11.x comorbidities.
- Stage 1 HTN (130–139/80–89 mmHg with high CVD risk, or Stage 2 ≥140/90): Pharmacotherapy initiated. First-line agents: thiazide diuretics, CCBs, ACE inhibitors, ARBs — choice guided by compelling indications (CKD → ACEi/ARB; HF → beta-blocker, ACEi/ARB, aldosterone antagonist; diabetes → ACEi/ARB).
- Resistant hypertension (BP uncontrolled on ≥3 agents including diuretic): Evaluate for secondary HTN (I15.x). Add mineralocorticoid receptor antagonist (spironolactone). Renal denervation is no longer purely investigational in the U.S.; FDA-approved renal denervation systems may be considered as adjunctive treatment for selected patients whose BP remains inadequately controlled despite lifestyle modification and antihypertensive medications, subject to coverage and patient-selection criteria.
- Hypertensive urgency (I16.0): Outpatient oral agent dose adjustment; BP goal is gradual reduction over 24–48 hours; avoid rapid reduction (risk of ischemic events). Oral labetalol, amlodipine, or clonidine commonly used.
- Hypertensive emergency (I16.1): ICU admission; IV antihypertensives (nicardipine, labetalol, clevidipine, nitroprusside, esmolol depending on end-organ damage type); goal: reduce MAP by ≤25% in first hour, then gradual normalization. Aortic dissection → esmolol + nitroprusside; ischemic stroke → permissive HTN until tPA threshold met; AKI/encephalopathy → nicardipine or labetalol.
Pulmonary Arterial Hypertension — Clinical Treatment
PAH treatment is risk-stratified per current ESC/ERS guidance using low/intermediate/high risk classification based on WHO functional class, 6-minute walk distance, BNP/NT-proBNP, cardiac imaging, and RHC hemodynamics:
- Low-risk (WHO FC I-II, stable): Oral combination therapy — ERA + PDE-5 inhibitor (e.g., ambrisentan + tadalafil, per AMBITION trial).
- Intermediate-risk (WHO FC II-III): Oral triple therapy (ERA + PDE-5i + oral prostacyclin receptor agonist [selexipag]); consider transition to parenteral prostacyclin.
- High-risk (WHO FC III-IV, rapidly deteriorating): IV prostacyclin (epoprostenol, treprostinil) is preferred; IV epoprostenol has the strongest mortality evidence. Bridge to lung transplantation evaluation.
- Vasodilator-reactive PAH (Group 1): Calcium channel blockers (diltiazem, nifedipine, amlodipine) — ONLY for patients who test positive on acute vasodilator challenge during RHC (minority of IPAH patients).
- CTEPH (Group 4): Pulmonary endarterectomy (PEA) surgery is the treatment of choice for operable disease; riociguat (Adempas) is approved for inoperable CTEPH; balloon pulmonary angioplasty (BPA) is an emerging option. Lifelong anticoagulation required.
- Group 2 PH (left heart disease): Treat the underlying cardiac condition (HF, valvular disease). PAH-targeted therapies are generally NOT used and may be harmful in Group 2 PH.
- Group 3 PH (lung disease/hypoxia): Optimize lung disease treatment; supplemental oxygen; inhaled treprostinil (Tyvaso inhalation solution and Tyvaso DPI) is FDA-approved for PH-ILD to improve exercise ability; Tyvaso DPI was approved in 2022.
- Lung transplantation: For refractory PAH (Group 1) or CTEPH not amenable to PEA; bilateral lung or heart-lung transplant depending on cardiac involvement. Document evaluation and listing status in record (Z76.82 if awaiting organ transplant; Z94.2 if post-lung transplant).
🎓 Patient Education / Summary
The following summary is designed for patient-facing use or for coding/CDI staff to communicate clinical context to documentation improvement initiatives.
What is Hypertension?
High blood pressure (hypertension) occurs when the force of blood pushing against artery walls is consistently too high. According to the American Heart Association, blood pressure is measured in two numbers: systolic (when the heart beats) over diastolic (when the heart rests). Normal is below 120/80 mmHg. Blood pressure at or above 130/80 mmHg in adults is classified as hypertension.
Why it matters for health: If left uncontrolled, high blood pressure damages blood vessels, the heart, kidneys, brain, and eyes over time. It is often called the “silent killer” because most people with hypertension have no symptoms. Regular monitoring and treatment are essential.
What is Pulmonary Hypertension?
Pulmonary hypertension (PH) is high blood pressure specifically in the lungs’ arteries. It is different from regular (systemic) hypertension. PH forces the right side of the heart to work harder to pump blood through the lungs, eventually leading to right heart failure (cor pulmonale) if untreated. Symptoms include worsening shortness of breath, fatigue, dizziness, and leg swelling. The Pulmonary Hypertension Association (PHA) is a patient resource for diagnosis, treatment, and support.
Key Lifestyle Recommendations (per AHA/ACC Guidelines)
- DASH diet — rich in fruits, vegetables, whole grains, low-fat dairy; limits sodium, saturated fat, red meat
- Limit sodium — target <2,300 mg/day (ideally <1,500 mg for HTN patients per DASH-Sodium trial)
- Regular exercise — 150 min/week moderate-intensity aerobic activity lowers BP by 5–8 mmHg
- Weight management — each kg of weight loss reduces BP ~1 mmHg
- Limit alcohol — ≤1 drink/day women, ≤2 drinks/day men
- Quit smoking — tobacco cessation reduces cardiovascular and renal risk (F17.2xx)
- Medication adherence — do not discontinue antihypertensives without physician guidance; rebound HTN can occur
- Home BP monitoring — log readings; typical target <130/80 mmHg at home for most adults per AHA 2017
CDI/Coder Quick Reference Summary
- I10 alone has NO HCC v28 — capture complications (I11.x, I12.x, I13.x) with full specificity
- HTN + CKD always → I12.x + N18.x (never I10 + N18.x)
- HTN + HF → I11.0 + I50.x type (physician link required)
- HTN + HF + CKD → I13.x + N18.x + I50.x
- PH Group coding → I27.0–I27.29 (not just I27.20) — query for group
- Cor pulmonale (I27.81) = HCC 226, the same HCC as pulmonary hypertension and chronic HF
- PAH prostacyclin-pathway therapies (epoprostenol, treprostinil, iloprost) → use specific HCPCS when applicable (e.g., J1325, J3285, J7686, Q4074) and DME pump/nebulizer codes when covered; verify payer-specific billing rules
- Pregnancy HTN → always O10.x–O16.x, never I10 during pregnancy
- PPHN in newborns → P29.3 (not I27.x)
About this Guide
This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY 2027 ICD-10-CM (effective October 1, 2026) and CPT 2027 (effective January 1, 2027). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.
Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)
Ready to turn this knowledge into a credential?
These Clinical Documentation Guides are a free companion to CCO’s paid training programs. Browse our full CCO Course, Blitz & Practice Exam Catalog — every core course, review blitz, practice exam, textbook, and free resource in one place — and find the perfect next step for your coding career.
CCO Hero
Know someone starting a medical coding career?
Share your personal CCO link. Your friend saves 20% on their first course or practice exam of $100 or more, and you earn 5% cash on their first enrollment over $100.
Become a CCO Hero